Form 8-K IDEAYA Biosciences, Inc. For: Apr 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- BofA lifts targets on AMD and ARM, raises CPU TAM to $170bn
Ideaya Biosciences (IDYA) PT Raised to $52 at Mizuho, 'we recommend being opportunistic'
April 13, 2026 3:08 PM EDTMizuho analyst Graig Suvannavejh raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $52.00 (from $46.00) while maintaining a Outperform rating.
The analyst comments "Following up on Quick Take comments earlier today (LINK) on positive P2/3 data for darovasertib/daro (a protein kinase C/PKC... More
Ideaya Biosciences (IDYA) PT Raised to $65 at Truist Securities
April 13, 2026 2:05 PM EDTTruist Securities analyst Greg Renza raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $65.00 (from $60.00) while maintaining a Buy rating.
The analyst comments "Today's disclosure highlights daro's best-in-class PFS and consistent efficacy to an earlier study which together with a favorable OS trend... More
